Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial

Overview of attention for article published in European Urology Oncology, August 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 1,050)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 52 news outlets
twitter: 21 X users

facebook: 1 Facebook page

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 38 X posts from 21 X users, with an upper bound of 67,436 followers.

#Universal #Germline #GeneticTesting Standard of Care for #Patients w/ #ProstateCancer: The Time Is Now c/w #PROCLAIM trial @Invitae https://t.co/BgunhuqIXk @EurUrolOncol https://t.co/LKlh85vQqM @JUrology https://t.co/4O52M0Y0PQ @JCOOP_ASCO @ASCO "..…

#Universal #Germline #GeneticTesting Standard of Care for #Patients w/ #ProstateCancer: The Time Is Now c/w #PROCLAIM trial https://t.co/BgunhuqIXk @EurUrolOncol https://t.co/LKlh85vQqM @JUrology https://t.co/4O52M0Y0PQ @JCOOP_ASCO @ASCO "...we recom…

@NCCN #germline #genetictesting guidelines updated to include #patients w/ #ProstateCancer, underscoring the medical necessity of #germlinetesting for these #patients c/w https://t.co/BgunhuqIXk @EurUrolOncol & https://t.co/Yf7D9uPIMx @JUrology #DrNe…

RT @EdEsplin: @NCCN misses 56% of #patients w/ #LynchSyndrome & 32% of #patients w/ #HBOC, & @NCCN worse in underrepresented population #pa…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 34 additional X posts.